Table 5.
Other prospective/retrospective studies related to the efficacy of everolimus in NETs
| Study, (year) | Design | n | Treatment | Primary | PFS | OS | ORR | SD |
|---|---|---|---|---|---|---|---|---|
| Panzuto (2014) [91] | Retro | 169 | Eve | P, GI, L | 12 mo | 32 mo | 8% | 68% |
| Berardi (2017) [92] | Retro | 116 | Eve | P | 19 mo | 44 mo | 10% | 73% |
| Liu (2016) [93] | Retro | 53 | Eve | P, GI | 18.9 mo | 63.9 mo | 28% | 55% |
| Lee (2017) [94] | Retro | 47 | Eve | P | 27.5 mo | 60.8 mo | 19% | 66% |
| Lee (2017) [95] | Retro | 40 | Eve | P | 20 mo | - | 0% | 65% |
| Yao (2015) [96] | Pro | 39 | Bv or Eve a → Bv + Eve |
P, GI, L | 14.6 mo | 27.9 mo | 25% | 69% |
| Kamp (2013) [97] | Retro | 24 | Eve | P, GI | 13.1 mo | - | 17% | 63% |
| Angelousi (2017) [98] | Retro | 21 11 |
Eve; 1st line Eve; 2nd line |
P P |
16.3 mo 15.5 mo |
(2-yr; 83%) (2-yr; 69%) |
- - |
- - |
| Yoo (2017) [99] | Retro | 11 6 |
Eve Eve |
P GI |
16.6 mo 14.7 mo |
Not reached 27.7 mo |
9% 17% |
73% 83% |
| Capdevila (2015) [100] | Retro | 57 | Eve + lanreotide | P, GI | 25.8 mo b | 26.4 mo | 18% | 61% |
Bv,bevacizumab; Eve, everolimus,; GI,gastrointestinal; L, lung; NET, neuroendocrine tumor; ORR, objective response rate; OS, overall survival; P, pancreas; PFS,progression free survival; Pro prospective; Retro, retrospective; SD, stable disease.
a
Treated with either agents alone for 3 weeks prior to combination therapy.
b
Reported as TTP (time to progression).